Cargando…
Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393790/ https://www.ncbi.nlm.nih.gov/pubmed/36003763 http://dx.doi.org/10.3389/fonc.2022.951215 |
_version_ | 1784771346282053632 |
---|---|
author | Rinaldi, Ikhwan Pratama, Samuel Wiyono, Lowilius Tandaju, Jeremy Rafael Wardhana, Indy Larasati Winston, Kevin |
author_facet | Rinaldi, Ikhwan Pratama, Samuel Wiyono, Lowilius Tandaju, Jeremy Rafael Wardhana, Indy Larasati Winston, Kevin |
author_sort | Rinaldi, Ikhwan |
collection | PubMed |
description | Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies and 1,105 healthy subjects as control were included. After two doses of COVID-19 vaccination, only 60% of cohorts with hematological malignancies were seroconverted compared to healthy controls (RR 0.60; 95%CI 0.50–0.71). A single dose of the vaccine resulted in a significantly lower seroconversion rate (RR 0.30; 95%CI 0.16–0.54). Non-Hodgkin lymphoma cohorts had the lowest rate of seroconversion (RR 0.5; 95%CI 0.35–0.71) and those who received active treatments had lower immunological responses (RR 0.59; 95%CI 0.46–0.75). Antibody titers were lower in cohorts with hematological malignancies without any differences in adverse effects in both groups. In conclusion, cohorts with hematological malignancies showed a lower seroconversion rate and antibody titers after receiving COVID-19 mRNA vaccines. The type of malignancy and the status of treatment had a significant impact on the response to vaccination. The vaccines were shown to be safe for both patients with hematological malignancies and healthy controls. Booster doses and stricter health protocols might be beneficial for patient populations. |
format | Online Article Text |
id | pubmed-9393790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93937902022-08-23 Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis Rinaldi, Ikhwan Pratama, Samuel Wiyono, Lowilius Tandaju, Jeremy Rafael Wardhana, Indy Larasati Winston, Kevin Front Oncol Oncology Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies and 1,105 healthy subjects as control were included. After two doses of COVID-19 vaccination, only 60% of cohorts with hematological malignancies were seroconverted compared to healthy controls (RR 0.60; 95%CI 0.50–0.71). A single dose of the vaccine resulted in a significantly lower seroconversion rate (RR 0.30; 95%CI 0.16–0.54). Non-Hodgkin lymphoma cohorts had the lowest rate of seroconversion (RR 0.5; 95%CI 0.35–0.71) and those who received active treatments had lower immunological responses (RR 0.59; 95%CI 0.46–0.75). Antibody titers were lower in cohorts with hematological malignancies without any differences in adverse effects in both groups. In conclusion, cohorts with hematological malignancies showed a lower seroconversion rate and antibody titers after receiving COVID-19 mRNA vaccines. The type of malignancy and the status of treatment had a significant impact on the response to vaccination. The vaccines were shown to be safe for both patients with hematological malignancies and healthy controls. Booster doses and stricter health protocols might be beneficial for patient populations. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9393790/ /pubmed/36003763 http://dx.doi.org/10.3389/fonc.2022.951215 Text en Copyright © 2022 Rinaldi, Pratama, Wiyono, Tandaju, Wardhana and Winston https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Rinaldi, Ikhwan Pratama, Samuel Wiyono, Lowilius Tandaju, Jeremy Rafael Wardhana, Indy Larasati Winston, Kevin Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title_full | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title_fullStr | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title_full_unstemmed | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title_short | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
title_sort | efficacy and safety profile of covid-19 mrna vaccine in patients with hematological malignancies: systematic review and meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393790/ https://www.ncbi.nlm.nih.gov/pubmed/36003763 http://dx.doi.org/10.3389/fonc.2022.951215 |
work_keys_str_mv | AT rinaldiikhwan efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT pratamasamuel efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT wiyonolowilius efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT tandajujeremyrafael efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT wardhanaindylarasati efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT winstonkevin efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis |